# Caution: checkpoint inhibitors in first-line ovarian cancer

Source: https://onco.cc/pairings/caution-pd1-first-line-ovarian/  
OnCo record `caution-pd1-first-line-ovarian` (Pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunotherapy added to first-line chemotherapy has failed to extend survival in ovarian cancer in every large trial so far; its only win is in PD-L1-positive platinum-resistant disease.

## Summary

IMagyn050 (atezolizumab), JAVELIN Ovarian 100 (avelumab), and DUO-O (durvalumab ± olaparib) showed no OS benefit in newly diagnosed disease. KEYNOTE-B96 (pembrolizumab + weekly paclitaxel) is the exception, in PD-L1-positive platinum-resistant relapse. Ovarian cancer is immunologically 'cold' with low TMB.

## Fields

- Kind: Pairing
- Last checked: 2026-09-07
- Pairs: Immune checkpoint inhibitors + Ovarian cancer
- Type: caution
- Rationale: Low neoantigen burden, immunosuppressive ascites, and myeloid-rich microenvironment blunt T-cell responses; chemotherapy-induced priming appears necessary for benefit.
- Evidence: Three negative first-line phase 3 trials; one positive relapsed-setting trial.

## Sources

- ClinicalTrials.gov NCT03737643: DUO-O / ENGOT-ov46: https://clinicaltrials.gov/study/NCT03737643
- ClinicalTrials.gov NCT05116189: KEYNOTE-B96 / ENGOT-ov65: https://clinicaltrials.gov/study/NCT05116189

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- trials: [DUO-O / ENGOT-ov46](https://onco.cc/trials/duo-o/), [KEYNOTE-B96 / ENGOT-ov65](https://onco.cc/trials/keynote-b96/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)

---
JSON: https://onco.cc/api/v1/entities/caution-pd1-first-line-ovarian.json